Measles vaccine given with a microneedle patch could boost immunization programs

November 27, 2012
This is a size comparison of a set of hypodermic needles of the kind now used to administer the measles vaccine, and an array of stainless steel microneedles that could be the basis for a patch that would be used to administer the vaccine. Credit: Gary Meek

Measles vaccine given with painless and easy-to-administer microneedle patches can immunize against measles at least as well as vaccine given with conventional hypodermic needles, according to research done by the Georgia Institute of Technology and the Centers for Disease Control and Prevention (CDC).

In the study, the researchers developed a technique to dry and stabilize the measles vaccine – which depends on a live attenuated virus – and showed that it remained effective for at least 30 days after being placed onto the . They also demonstrated that the dried vaccine was quickly released in the skin and able to prompt a potent immune response in an .

The microneedle technique could provide a new tool for international immunization programs against measles, which killed nearly 140,000 children in 2010. The research was reported online October 5 in the journal Vaccine, and will appear in a special issue of the journal. The research was supported by the Georgia Research Alliance – and indirectly by the Division of Viral Diseases and Animal Resources Branch of the CDC, and by the National Institutes of Health through its support of efforts to develop a microneedle-based .

"We showed in this study that measles vaccine delivered using a microneedle patch produced an immune response that is indistinguishable from the response produced when the vaccine is delivered subcutaneously," said Chris Edens, the study's first author and a graduate student in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.

Measles immunization programs now use conventional to deliver the vaccine. Large global immunization programs therefore require significant logistical support because the vaccine must be kept refrigerated, large numbers of needles and syringes must be shipped, and the ten-dose vaccine vials must be reconstituted with before use.

Because it requires a hypodermic needle injection, measles must be carried out by trained medical personnel. Finally, used needles and syringes must be properly disposed of to prevent potential disease transmission or reuse.

Use of microneedle patches could eliminate the need to transport needles, syringes and sterile water, reducing logistical demands. Vaccination could be done by personnel with less medical training, who would simply apply the patches to the skin and remove them after several minutes, making possible door-to-door campaigns similar to those used in polio vaccination. Single-use patches could also reduce the waste of vaccine that occurs when all ten doses in a vial cannot be used.

"A major advantage would be the ease of delivery," said Mark Prausnitz, a professor in the Georgia Tech School of Chemical and Biomolecular Engineering, and one of the inventors of the microneedle patch. "Microneedles would allow us to move away from central locations staffed by health care personnel to the use of minimally-trained personnel who would go out to homes to administer the vaccine."

Many countries in the Western Hemisphere have eliminated endemic transmission of the disease, though travelers often serve as sources for imported cases. However, measles remains the leading cause of vaccine-preventable death among children elsewhere in the world, prompting interest in alternative vaccination techniques.

Researchers show the size and volume differential of microneedles and traditional hypodermic needles. Shown (left) holding a microneedle patch is Chris Edens of Georgia Tech, while Mark Prausnitz (right) of Georgia Tech holds examples of the hypodermic needle and syringe that is now used for measles vaccination. Also shown are Marcus Collins and Paul Rota of the CDC. Credit: Gary Meek

"Measles is extremely infectious, and we need an immunization coverage rate of around 95 percent to interrupt its transmission," said Dr. Paul Rota, Measles Laboratory Team Lead of CDC's Division of Viral Diseases and one of the study's co-authors. "Microneedles represent a real potential game-changer in developing strategies to get high global coverage for a measles vaccine."

In their study, the CDC-Georgia Tech team first faced the challenge of converting a liquid vaccine to a formulation that could be readily applied to stainless steel microneedles and dried for packaging. The work was made more difficult by the fact that the vaccine contains an attenuated live virus whose integrity had to be maintained.

The researchers began by studying materials that could be combined with the vaccine to improve its stability in dry form. Ultimately, they obtained the best results by adding a sugar known as trehalose to the liquid vaccine. That formulation was applied to the microneedles – which were about 750 microns long – by dipping them into the solution and allowing the liquid to dry. The vaccine dose on the microneedles was controlled by the number of times the microneedles were dipped into the solution.

Cotton rats (Sigmodon hispidus) used in the study were divided into seven groups of five animals each for the testing. The comparison showed that vaccination with the microneedle technique produced an immune response that was statistically indistinguishable from that produced by vaccination with the hypodermic needles.

"The two major accomplishments of this study are that the vaccine can be stabilized on microneedles, and that it could dissolve in the skin to provide a good immune response," Rota said.

To advance the microneedle technique, the researchers are now working to improve the stability of the dry vaccine with the goal of eliminating the need for refrigeration. They are also studying the use of polymer-based microneedles that would fully dissolve in the skin, removing the need to dispose of potentially infectious waste.

Ultimately, a microneedle-based measles vaccine will need to be evaluated for safety and efficacy in a non-human primate model and in several clinical trials before it can be used routinely in humans.

Microneedles are also being studied for administration of vaccines against influenza, polio, rotavirus, tuberculosis, and hepatitis B. The microneedle would likely find its first use in the developing world as part of measles elimination campaigns, and would probably not replace the Measles-Mumps-Rubella (MMR) used in the United States.

"This represents a different direction for us, which is campaign-mode global health vaccination," said Prausnitz. "I see the greatest impact of the measles patch being in developing-country vaccination programs where the logistical advantages of this simple-to-use technology will have the most public health benefit."

In addition to those already mentioned, the research team included Marcus L. Collins and Jessica Ayers, both from the CDC.

This research is supported by the Georgia Research Alliance (GRA) with indirect support from the Division of and Animal Resources Branch of the (CDC) and the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, CDC or GRA.

Mark Prausnitz is an inventor on patents and has a significant financial interest in a company that is developing microneedle-based products. This potential conflict of interest has been disclosed and is being managed by Georgia Tech and Emory University.

Explore further: Grant funds feasibility study of microneedle patches for polio vaccination

More information: Edens C., et al. "Measles vaccination using a microneedle patch," Vaccine (2012). dx.doi.org/10.1016/j.vaccine.2012.09.062

Related Stories

Grant funds feasibility study of microneedle patches for polio vaccination

November 7, 2011
The Georgia Institute of Technology will receive funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that ...

Microneedle vaccine patch boosts flu protection through robust skin cell immune response

March 6, 2012
Recent research found that microneedle vaccine patches are more effective at delivering protection against influenza virus in mice than subcutaneous or intramuscular inoculation. A new, detailed analysis of the early immune ...

Study shows H1N1 microneedle vaccine protects better than injection

July 12, 2011
(Medical Xpress) -- A vaccine delivered to the skin using a microneedle patch gives better protection against the H1N1 influenza virus than a vaccine delivered through subcutaneous or intramuscular injection, researchers ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.